{"title":"Initial experience of high-dose helical tomotherapy for medically inoperable esophageal cancer patients","authors":"E. Tate, Y. Hama, M. Hashimoto","doi":"10.46459/pmu.2020005","DOIUrl":null,"url":null,"abstract":": Purpose: Helical tomotherapy (HT) is one of the radiotherapy methods that has become widespread in recent years. The aim of this study is to investigate the safety of high-dose HT for medically inoperable esophageal cancer that is unable to tolerate chemoradiotherapy. Methods: Eight patients with medically inoperable esophageal squamous cell carcinoma who cannot tolerate chemoradiotherapy were irradiated to 60 Gy at 2 Gy/fraction with HT. Results: The 1-, and 2-year overall survival rate were 75.0%, and 46.9%, respectively. The 1-, and 2-year locoregional recurrence-free survival rate ware 72.9%, and 72.9%, respectively. Three patients developed grade 2 or 3 hematological acute toxicity, and one patient developed grade 2 late pericardial effusion. Conclusions: Medically inoperable patients with esophageal cancer who cannot tolerate chemoradiotherapy might be treated safely by high-dose HT with minimal adverse events.","PeriodicalId":101009,"journal":{"name":"Personalized Medicine Universe","volume":"27 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2020-10-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Personalized Medicine Universe","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.46459/pmu.2020005","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
: Purpose: Helical tomotherapy (HT) is one of the radiotherapy methods that has become widespread in recent years. The aim of this study is to investigate the safety of high-dose HT for medically inoperable esophageal cancer that is unable to tolerate chemoradiotherapy. Methods: Eight patients with medically inoperable esophageal squamous cell carcinoma who cannot tolerate chemoradiotherapy were irradiated to 60 Gy at 2 Gy/fraction with HT. Results: The 1-, and 2-year overall survival rate were 75.0%, and 46.9%, respectively. The 1-, and 2-year locoregional recurrence-free survival rate ware 72.9%, and 72.9%, respectively. Three patients developed grade 2 or 3 hematological acute toxicity, and one patient developed grade 2 late pericardial effusion. Conclusions: Medically inoperable patients with esophageal cancer who cannot tolerate chemoradiotherapy might be treated safely by high-dose HT with minimal adverse events.